Long-Term Interferon Maintenance Therapy Improves Survival in Patients with HCV-Related Hepatocellular Carcinoma after Curative Radiofrequency Ablation
Masatoshi Kudo(Kindai University), Kazuomi Ueshima(Kindai University), Satoshi Kitai(Kindai University), Shunsuke Takahashi(Kanagawa Dental University), Yasunori Minami, Kinuyo Hatanaka(Union Hospital), Tatsuo Inoue, Emi Ishikawa(Kyowa Chemical Industry (Japan)), Satoru Hagiwara(Kindai University Hospital), Yasuhiro Sakaguchi(Jikei University Kashiwa hospital), Hobyung Chung(Kindai University)
Cited by 66
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Development of a Prokaryotic Universal Primer for Simultaneous Analysis of Bacteria and Archaea Using Next-Generation Sequencing
|PLoS ONE|2014|1.5k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k